SHARE OPTION PLANS AND ESPP (Tables)

6 Months Ended

Jun. 30, 2025

Share-Based Payment Arrangement, Recognized Amount [Abstract]

Schedule of stock option plans

A summary of the status of the Company’s option plans as of June 30, 2025 and changes during the period then ended is presented below:

	Six months ended June 30, 2025
	Unaudited
	Number of options	Weighted average exercise price
Outstanding at beginning of year	11,315,468	$	31.41
Granted	944,888	17.96
Exercised	(365,676)	15.03
Forfeited and canceled	(387,966)	40.89
Outstanding as of June 30, 2025	11,506,714	$	30.50
Exercisable options	7,362,522	$	35.14

Schedule of RSUs and PSUs

A summary of the status of the Company’s RSUs and PSUs as of June 30, 2025 and changes during the period then ended is presented below.

	Six months ended June 30, 2025
	Unaudited
	Number of RSU/PSUs	Weighted average grant date fair value
Unvested at beginning of year	12,066,515	$	27.19
Granted	5,165,100	19.02
Vested	(2,775,003)	24.22
Forfeited and cancelled	(788,207)	39.11
Unvested as of June 30, 2025 (1)	13,668,405	24.02

(1) Includes PSUs that have a mix of service, market and other milestone performance vesting conditions which are vested upon achievements of performance milestones that are not probable as of June 30, 2025, in accordance with ASC 718 "Compensation — Stock Compensation" as follows:

June 30, 2025
Number of PSUs	Fair value at grant date per PSU		Total fair value at grant date
704,493	$	16.30	$	11,483
1,154,720	18.19		21,004
21,653	19.44		421
901,284	48.16		43,406
73,186	76.97		5,633
2,855,336			$	81,947

Schedule of fair value assumptions used for all equity based awards estimated using black-scholes option pricing model

The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model. The Company assessed fair value using the following underlying assumptions: 

	Six months ended June 30,				Year ended December 31, 2024
	2025		2024
	Unaudited				Audited
Stock Option Plans
Expected term (years)	5.50-5.79		5.50-5.73		5.50-5.73
Expected volatility	75%-77%		71%-73%		71%-73%
Risk-free interest rate	4.01%-4.02%		3.88%-4.43%		3.88%-4.43%
Dividend yield	0.00	%	0.00	%	0.00	%
ESPP
Expected term (years)	0.50		0.50		0.50
Expected volatility	89	%	90	%	73%-90%
Risk-free interest rate	4.16	%	5.13	%	5.13%-5.23%
Dividend yield	0.00	%	0.00	%	0.00	%

Schedule of non-cash share-based compensation expense related to company's equity-based awards

The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and six months ended June 30, 2025 and 2024, and the year ended December 31, 2024 was:

	Three months ended June 30,				Six months ended June 30,				Year ended December 31, 2024
	2025		2024		2025		2024
	Unaudited				Unaudited				Audited
Cost of revenues	$	973	$	1,698	$	2,075	$	3,446	$	6,873
Research, development and clinical studies	5,787		9,517		11,988		18,127		32,716
Sales and marketing	5,358		9,896		13,875		20,944		43,097
General and administrative	14,025		10,719		27,757		23,397		77,349
Total share-based compensation expense	$	26,143	$	31,830	$	55,695	$	65,914	$	160,035